HALOZYME THERAPEUTICS, INC. (HALO) Total liabilities 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) total liabilities at each fiscal year-end, per SEC filings.
$2.5BFY2025 · since FY2016: $294.0M → $2.5B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.5B | +45.7% |
| FY2024 | $1.7B | +3.0% |
| FY2023 | $1.6B | -1.3% |
| FY2022 | $1.7B | +84.2% |
| FY2021 | $907.5M | +111.6% |
| FY2020 | $428.9M | -9.5% |
| FY2019 | $474.1M | +147.8% |
| FY2018 | $191.4M | -38.6% |
| FY2017 | $311.6M | +6.0% |
| FY2016 | $294.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice